Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volanesorsen in familial partial lipodystrophy with hypertriglyceridemia and uncontrolled diabetes
NL-OMON44784Phase 2Active, not recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jun 2016
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of volanesorsen in familial partial lipodystrophy (FPLD), hypertriglyceridemia and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Ionis Pharmaceuticals. Primary endpoint: Percent change from baseline in fasting triglycerides at Month 3. Started Jun 2016; status: active, not recruiting.
02
Drugs
volanesorsen
03
Conditions
familial partial lipodystrophy (FPLD)hypertriglyceridemiatype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON44784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44784.